Literature DB >> 18654921

Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus.

Alessandro C Pasqualotto1.   

Abstract

Most of the information available about Aspergillus infections has originated from the study of A. fumigatus, the most frequent species in the genus. This review aims to compare the pathogenicity and clinical aspects of Aspergillosis caused by A. fumigatus an A. flavus. Experimental data suggests that A. flavus is more virulent than A. fumigatus. However, these were mostly models of disseminated Aspergillus infection which do not properly mimic the physiopathology of invasive aspergillosis, a condition that is usually acquired by inhalation. In addition, no conclusive virulence factor has been identified for Aspergillus species. A. flavus is a common cause of fungal sinusitis and cutaneous infections. Chronic conditions such as chronic cavitary pulmonary aspergillosis and sinuses fungal balls have rarely been associated with A. flavus. The bigger size of A. flavus spores, in comparison to those of A. fumigatus spores, may favour their deposit in the upper respiratory tract. Differences between these species justify the need for a better understanding of A. flavus infections.

Entities:  

Mesh:

Year:  2008        PMID: 18654921     DOI: 10.1080/13693780802247702

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  44 in total

1.  Investigation of Multiple Resistance Mechanisms in Voriconazole-Resistant Aspergillus flavus Clinical Isolates from a Chest Hospital Surveillance in Delhi, India.

Authors:  Cheshta Sharma; Rakesh Kumar; Nitin Kumar; Aradhana Masih; Dinesh Gupta; Anuradha Chowdhary
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

2.  Genetic Diversity and In Vitro Antifungal Susceptibility of 200 Clinical and Environmental Aspergillus flavus Isolates.

Authors:  Mojtaba Taghizadeh-Armaki; Mohammad Taghi Hedayati; Saham Ansari; Saeed Mahdavi Omran; Sasan Saber; Haleh Rafati; Jan Zoll; Henrich A van der Lee; Willem J G Melchers; Paul E Verweij; Seyedmojtaba Seyedmousavi
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  A study of air microbe levels in different areas of a hospital.

Authors:  Ginés Ortiz; Genoveva Yagüe; Manuel Segovia; Vicente Catalán
Journal:  Curr Microbiol       Date:  2009-03-28       Impact factor: 2.188

4.  Molecular variation analysis of Aspergillus flavus using polymerase chain reaction-restriction fragment length polymorphism of the internal transcribed spacer rDNA region.

Authors:  Majid Zarrin; Maryam Erfaninejad
Journal:  Exp Ther Med       Date:  2016-06-24       Impact factor: 2.447

5.  Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis.

Authors:  Shivaprakash M Rudramurthy; Seyedmojtaba Seyedmousavi; Manpreet Dhaliwal; Arunaloke Chakrabarti; Jacques F Meis; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

6.  Cutaneous model of invasive aspergillosis.

Authors:  Ronen Ben-Ami; Russell E Lewis; Konstantinos Leventakos; Jean-Paul Latgé; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2010-02-09       Impact factor: 5.191

Review 7.  Aspergillus flavus malignant external otitis in a diabetic patient: case report and literature review.

Authors:  Maud Pichon; Véronique Joly; Nicolas Argy; Sandrine Houze; Stéphane Bretagne; Alexandre Alanio; Michel Wassef; Benjamin Verillaud; Yazdan Yazdanpanah
Journal:  Infection       Date:  2020-02-08       Impact factor: 3.553

8.  Diagnosis and treatment of paranasal sinus fungus ball of odontogenic origin: case report.

Authors:  E Fanucci; M Nezzo; L Neroni; L Montesani; L Ottria; M Gargari
Journal:  Oral Implantol (Rome)       Date:  2014-04-04

9.  In vitro antifungal susceptibility of clinically relevant species belonging to Aspergillus section Flavi.

Authors:  Sarah S Gonçalves; Alberto M Stchigel; Josep Cano; Josep Guarro; Arnaldo L Colombo
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

10.  NAC is associated with additional alleviation of lung injury induced by invasive pulmonary aspergillosis in a neutropenic model.

Authors:  Peng Xu; Jie-Ming Qu; Jin-Fu Xu; Jing Zhang; Hong-Ni Jiang; Hui-Jun Zhang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.